Antibody response to feline panleukopenia virus vaccination in cats with asymptomatic retrovirus infections: a pilot study

Autor: Bergmann, Michèle, Schwertler, Stephanie, Speck, Stephanie, Truyen, Uwe, Hartmann, Katrin

ObjectivesCurrently, there are only a few studies on how immunocompromised cats, such as cats infected with feline leukaemia virus (FeLV) and feline immunodeficiency virus (FIV), respond to vaccination. Therefore, this study measured feline panleukop

Externí odkaz: https://ul.qucosa.de/id/qucosa%3A84059
https://ul.qucosa.de/api/qucosa%3A84059/attachment/ATT-0/

Updates and advances in the treatment of Parkinson disease

Autor: Thomas E. Kimber, Michael Hayes, Victor S.C. Fung, John D. O'Sullivan

Publikováno v: Medical Journal of Australia. 211:277-283

Parkinson disease (PD) is a complex neurodegenerative disorder that can present heterogeneously with a combination of motor and non-motor symptoms. α-synuclein, a neuronal protein, can undergo aberrant conformational change resulting in the intra-ne

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::832192c0233f824325d0010babc5000d
https://doi.org/10.5694/mja2.50224

Current status of nicotine vaccines: A narrative review

Autor: Alberto Salazar-Juárez, S. Barbosa Méndez

Publikováno v: Vacunas (English Edition). 19:67-78

Introduction The classical pharmacopoeia used to attenuate drug dependence of illegal abuse, as well as nicotine, has shown poor therapeutic efficacy. Based on this clinical-therapeutic perspective, for more than a decade several researchers have dev

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a15ebed4161aa8139cbbf9cd15ff3748
https://doi.org/10.1016/j.vacune.2018.09.001

Identifikation neuer CD8+ T-Zellepitope des Respiratorischen Synzytial-Virus zur Anwendung in der Immuntherapie

Autor: Burbulla, Daniel

Das humane Respiratorische Synzytial-Virus ist der häufigste Auslöser einer unteren Atemwegsinfektion bei Kindern und Neugeborenen sowie eine weit verbreitete Krankheitsursache bei Immungeschwächten und älteren Erwachsenen. Bis heute steht keine

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::866b18d8bad8b44620b4f9e1c273ec43
https://hdl.handle.net/10900/84131

Estimation of the individual residual risk of cervical cancer after vaccination with the nonavalent HPV vaccine

Autor: Didier Riethmuller, Susanne K. Kjaer, Pierre Van Damme, Rosybel Drury, Kaatje Bollaerts, Elmar A. Joura, Karl Ulrich Petry, Chris J.L.M. Meijer, Paolo Bonanni, Margaret Stanley, Xavier Bosch, Benoît Soubeyrand

Publikováno v: Dipòsit Digital de la UB
Universidad de Barcelona
Human vaccines & immunotherapeutics
Human Vaccines & Immunotherapeutics
Petry, K U, Bollaerts, K, Bonanni, P, Stanley, M, Drury, R, Joura, E, Kjaer, S K, Meijer, C J L M, Riethmuller, D, Soubeyrand, B, Van Damme, P & Bosch, X 2018, ' Estimation of the individual residual risk of cervical cancer after vaccination with the nonavalent HPV vaccine ', Human Vaccines and Immunotherapeutics, vol. 14, no. 7, pp. 1800-1806 . https://doi.org/10.1080/21645515.2018.1450125

Background: The nonavalent HPV (9vHPV) vaccine is indicated for active immunisation of individuals from the age of 9 years against cervical, vulvar, vaginal and anal premalignant lesions and cancers causally related to vaccine HPV high risk types 16,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45a9c03b652773a248bf47be6dbb4278
http://hdl.handle.net/2445/172773